Why could passive Immunoglobulin E antibody therapy be safe in clinical oncology?

Clinical and Experimental Allergy

Volumn 41, Issue 10, 2011, Pages 1337-1340

  Jensen Jarolim, E ^a   Singer, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FC RECEPTOR; IMMUNOGLOBULIN E ANTIBODY; INFLIXIMAB; OMALIZUMAB; PANITUMUMAB; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

ANAPHYLAXIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BASOPHIL; BREAST METASTASIS; CANCER IMMUNOTHERAPY; COLON CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DESIGN; DRUG SAFETY; EDITORIAL; EOSINOPHIL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHANGIOGENESIS; MACROPHAGE; MAST CELL; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PSORIASIS; RECEPTOR BINDING; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BASOPHILS; CARCINOMA; FEMALE; FOLATE RECEPTOR 1; HUMANS; HYPERSENSITIVITY, IMMEDIATE; OVARIAN NEOPLASMS; RECEPTORS, IGE;

EID: 80052969480     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03764.x     Document Type: Editorial

References (41)

1. Zheng L, Li B, Qian Wet al. Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. Biochem Biophys Res Commun 2008; 375:619-22.
2. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P.Safety andtolerability of omalizumab. Clin Exp Allergy 2009; 39:788-97.
3. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ.Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011; 33:857-69.
4. Kurzeja M, Rudnicka L, Olszewska M.New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011; 12:113-25.
5. Saif MW, Kaley K, Chu E, Copur MS.Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer 2010; 9:315-8.
6. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM.Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11.
7. Schmitz KR, Ferguson KM.Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res 2009; 315:659-70.
8. Lordick F. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. Future Oncol 2011; 7:187-99.
9. Ghosh R, Narasanna A, Wang SEet al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 2011; 71:1871-82.
10. Yan L, Hsu K, Beckman RA.Antibody-based therapy for solid tumors. Cancer J 2008; 14:178-83.
11. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM.Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 2007; 179:2815-23.
12. Cohen J, Wilson A.New challenges to medicare beneficiary access to mAbs. MAb J 2009; 1:56-66.
13. Reichert JM, Wenger JB.Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008; 13:30-7.
14. Lohse S, Derer S, Beyer Tet al. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol 2011; 186:3770-8.
15. Weiner LM, Surana R, Wang S.Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27.
16. Jensen-Jarolim E, Achatz G, Turner MCet al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 2008; 63:1255-66.
17. Gould HJ, Mackay GA, Karagiannis SNet al. Comparison of IgE, IgG antibody-dependent cytotoxicity in vitro andin a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 1999; 29:3527-37.
18. Karagiannis SN, Wang Q, East Net al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 2003; 33:1030-40.
19. Karagiannis SN, Bracher MG, Hunt Jet al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007; 179:2832-43.
20. Karagiannis SN, Bracher MG, Beavil RLet al. Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother 2008; 57:247-63.
21. Karagiannis P, Singer J, Hunt Jet al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother 2009; 58:915-30.
22. Kershaw MH, Darcy PK, Trapani JA, MacGregor D, Smyth MJ.Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res 1998; 10:133-42.
23. Pullyblank AM, Guillou PJ, Monson JR.Interleukin 1 and tumour necrosis factor alpha may be responsible for the lytic mechanism during anti-tumour antibody-dependent cell-mediated cytotoxicity. Br J Cancer 1995; 72:601-6.
24. Green S, Dobrjansky A, Carswell EAet al. Partial purification of a serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1976; 73:381-5.
25. Buttel IC, Chamberlain P, Chowers Yet al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 2011; 39:100-9.
26. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M.Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol 2011; 127:S67-73.
27. Fu SL, Pierre J, Smith-Norowitz TAet al. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 2008; 153:401-9.
28. Neuchrist C, Kornfehl J, Grasl Met al. Distribution of immunoglobulins in squamous cell carcinoma of the head and neck. Int Arch Allergy Immunol 1994; 104:97-100.
29. Zennaro D, Capalbo C, Scala Eet al. IgE, IgG4 and IgG response to tissue-specific and environmental antigens in patients affected by cancer 30th Congress of the European Academy of Allergy and Clinical Immunology, Istanbul, 2011.
30. Larche M, Akdis CA, Valenta R.Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761-71.
31. Perez-Montfort R, Metzger H.Proteolysis of soluble IgE-receptor complexes: localization of sites on IgE which interact with the Fc receptor. Mol Immunol 1982; 19:1113-25.
32. Jensen-Jarolim E, Mechtcheriakova D, Pali-Schoell IThe targets of IgE: allergen-associated and tumor-associated molecular patterns. In: Penichet M, Jensen-Jarolim E, eds. Cancer and IgE: introducing the concept of AllergoOncology. New York: Humana Press, 2010; 231-54.
33. Brigati C, Noonan DM, Albini A, Benelli R.Tumors andinflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002; 19:247-58.
34. Legrand F, Driss V, Delbeke Met al. Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol 2010; 185:7443-51.
35. Rudman SM, Josephs DH, Cambrook Het al. Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of Fce{open}RI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy 2011; 41 (this issue).
36. Black PH. Shedding from normal and cancer-cell surfaces. N Engl J Med 1980; 303:1415-6.
37. Pavlakovic H, Becker J, Albuquerque R, Wilting J, Ambati J.Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors. Ann N Y Acad Sci 2010; 1207(Suppl. 1):E7-15.
38. Weichselbaumer M, Willmann M, Reifinger Met al. Phylogenetic discordance of human and canine carcinoembryonic antigen (CEA, CEACAM) families, but striking identity of the CEA receptors will impact comparative oncology studies. PLOS Curr 2011; 3:RRN 1223.
39. Najy AJ, Day KC, Day ML.The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 2008; 283:18393-401.
40. Clifton GT, Sears AK, Clive KSet al. Folate receptor alpha: a storied past and promising future in immunotherapy. Hum Vaccin 2011; 7 [Epub ahead of print].
41. Dibbern DA Jr, Palmer GW, Williams PB, Bock SA, Dreskin SC.RBL cells expressing human Fc epsilon RI are a sensitive tool for exploring functional IgE-allergen interactions: studies with sera from peanut-sensitive patients. J Immunol Methods 2003; 274:37-45.